Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

Michael R. Martino; Manuel Gutiérrez-Aguilar; Nicole K.H. Yiew; Andrew J. Lutkewitte; Jason M. Singer; Kyle McCommis; Daniel Ferguson; Kim H.H. Liss; Jun Yoshino; M. Katie Renkemeyer; Gordon Smith; Kevin Cho; Justin A. Fletcher; Samuel Klein; Gary J. Patti; Shawn C. Burgess; Brian N. Finck

doi:10.1016/j.celrep.2022.111633

Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

Michael R. Martino, Manuel Gutiérrez-Aguilar, Nicole K.H. Yiew, Andrew J. Lutkewitte, Jason M. Singer, Kyle McCommis, Daniel Ferguson, Kim H.H. Liss, Jun Yoshino, M. Katie Renkemeyer, Gordon Smith, Kevin Cho, Justin A. Fletcher, Samuel Klein, Gary J. Patti, Shawn C. Burgess, Brian N. Finck

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

(Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

Original language	English
Article number	111633
Journal	Cell Reports
Volume	41
Issue number	7
DOIs	https://doi.org/10.1016/j.celrep.2022.111633
State	Published - Nov 15 2022

Access to Document

10.1016/j.celrep.2022.111633

Fingerprint

Dive into the research topics of 'Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))'. Together they form a unique fingerprint.

Cite this

Martino, M. R., Gutiérrez-Aguilar, M., Yiew, N. K. H., Lutkewitte, A. J., Singer, J. M., McCommis, K., Ferguson, D., Liss, K. H. H., Yoshino, J., Renkemeyer, M. K., Smith, G., Cho, K., Fletcher, J. A., Klein, S., Patti, G. J., Burgess, S. C., & Finck, B. N. (2022). Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733)). Cell Reports, 41(7), Article 111633. https://doi.org/10.1016/j.celrep.2022.111633

@article{d4685e0357a94853beca806be808a806,

title = "Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))",

abstract = "(Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.",

author = "Martino, {Michael R.} and Manuel Guti{\'e}rrez-Aguilar and Yiew, {Nicole K.H.} and Lutkewitte, {Andrew J.} and Singer, {Jason M.} and Kyle McCommis and Daniel Ferguson and Liss, {Kim H.H.} and Jun Yoshino and Renkemeyer, {M. Katie} and Gordon Smith and Kevin Cho and Fletcher, {Justin A.} and Samuel Klein and Patti, {Gary J.} and Burgess, {Shawn C.} and Finck, {Brian N.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = nov,

day = "15",

doi = "10.1016/j.celrep.2022.111633",

language = "English",

volume = "41",

journal = "Cell Reports",

issn = "2639-1856",

number = "7",

}

Martino, MR, Gutiérrez-Aguilar, M, Yiew, NKH, Lutkewitte, AJ, Singer, JM, McCommis, K, Ferguson, D , Liss, KHH, Yoshino, J, Renkemeyer, MK, Smith, G, Cho, K, Fletcher, JA, Klein, S , Patti, GJ, Burgess, SC & Finck, BN 2022, 'Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))', Cell Reports, vol. 41, no. 7, 111633. https://doi.org/10.1016/j.celrep.2022.111633

Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733)). / Martino, Michael R.; Gutiérrez-Aguilar, Manuel; Yiew, Nicole K.H. et al.
In: Cell Reports, Vol. 41, No. 7, 111633, 15.11.2022.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

AU - Martino, Michael R.

AU - Gutiérrez-Aguilar, Manuel

AU - Yiew, Nicole K.H.

AU - Lutkewitte, Andrew J.

AU - Singer, Jason M.

AU - McCommis, Kyle

AU - Ferguson, Daniel

AU - Liss, Kim H.H.

AU - Yoshino, Jun

AU - Renkemeyer, M. Katie

AU - Smith, Gordon

AU - Cho, Kevin

AU - Fletcher, Justin A.

AU - Klein, Samuel

AU - Patti, Gary J.

AU - Burgess, Shawn C.

AU - Finck, Brian N.

PY - 2022/11/15

Y1 - 2022/11/15

N2 - (Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

AB - (Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

UR - http://www.scopus.com/inward/record.url?scp=85141926820&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2022.111633

DO - 10.1016/j.celrep.2022.111633

M3 - Comment/debate

C2 - 36384117

AN - SCOPUS:85141926820

SN - 2639-1856

VL - 41

JO - Cell Reports

JF - Cell Reports

IS - 7

M1 - 111633

ER -

Martino MR, Gutiérrez-Aguilar M, Yiew NKH, Lutkewitte AJ, Singer JM, McCommis K et al. Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733)). Cell Reports. 2022 Nov 15;41(7):111633. doi: 10.1016/j.celrep.2022.111633

Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

Abstract

Access to Document

Other files and links

Fingerprint

Cite this